Drug intelligence / Profile preview

MB2001

Development stage: Preclinical
Lead developer: Mainline Biosciences
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules

Overview

MB2001 is a peptide-drug conjugate under preclinical development by Mainline Biosciences. It acts as a modulator of Ephrin type-A receptor 2 (EphA2), a receptor tyrosine kinase implicated in cancer progression and metastasis. The drug is being investigated for the treatment of neoplasms, with its primary mechanism involving modulation of EphA2 signaling pathways to inhibit tumor growth and spread.

Targets

EPHA2 (Ephrin type-A receptor 2)

Beyond the preview

Go deeper on MB2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB2001.

Explore the full profile